Health & Fitness
Thu, March 1, 2012Wed, February 29, 2012Tue, February 28, 2012Mon, February 27, 2012Sat, February 25, 2012Fri, February 24, 2012Thu, February 23, 2012Wed, February 22, 2012Tue, February 21, 2012Mon, February 20, 2012Sat, February 18, 2012Fri, February 17, 2012Savient Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
Published in Health and Fitness on Thursday, February 23rd 2012 at 13:16 GMT by Market Wire
Savient Pharmaceuticals to Present at the Cowen and Company 32nd Annual... -- EAST BRUNSWICK, N.J., Feb. 23, 2012 /PRNewswire/ --
Savient Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
EAST BRUNSWICK, N.J., Feb. 23, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: [ SVNT ]) today announced that Kenneth Zuerblis, Executive Vice President and Chief Financial Officer of Savient will present at the Cowen and Company 32nd Annual Health Care Conference on Tuesday, March 6, 2012 at 10:40 AM Eastern Time. The conference will be held at the Boston Marriott Copley Place in Boston, MA.
A live webcast of the presentation can be accessed through the investor relations section of the Company's website at [ www.savient.com ]. Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.
ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at [ www.savient.com ].
Contact: |
|
Mary Coleman | Carney Noensie |
Savient Pharmaceuticals, Inc. | Burns McClellan |
(732) 418-9300 | (212) 213-0006 |
SVNT - G
SOURCE Savient Pharmaceuticals, Inc.
[ Back to top ] RELATED LINKS
[ http://www.savient.com ]
